Dear reader of ADxS.org, please excuse the disruption.

ADxS.org needs about $63500 in 2024. In 2023 we received donations of about $ 32200. Unfortunately, 99.8% of our readers do not donate. If everyone who reads this request makes a small contribution, our fundraising campaign for 2024 would be over after a few days. This donation request is displayed 23,000 times a week, but only 75 people donate. If you find ADxS.org useful, please take a minute and support ADxS.org with your donation. Thank you!

Since 01.06.2021 ADxS.org is supported by the non-profit ADxS e.V..

$8975 of $63500 - as of 2024-02-29
14%
ADxS.org Logo
ADxS.org Logo
Search Donations Addresses Recent changes ADHS-Forum Deutsche Version
Register

Already have an account? Login

Header Image
Norbinaltorphimine for ADHD

Sitemap

The ADxS.org project
Abstract from ADxS.org
Symptoms
Consequences of ADHD
Origin
Stress
Neurological aspects
Diagnostics
Prevention
Treatment and therapy
Medication for ADHD - Overview
Choice of medication for ADHD or ADHD with comorbidity
Dosing of medication for ADHD
Suitable medication for ADHD
Experimental medication for ADHD
Sleep disorder-related medication for ADHD
Appetite-enhancing medication for ADHD
Medication for ADHD in development
Less suitable medication for ADHD
Vitamins, minerals, dietary supplements for ADHD
Plant extracts for ADHD
Medication and drugs - the difference
Substance abuse with self-medication effect in ADHD
Addresses
This and that about ADHD
Tests and surveys
Forum

Norbinaltorphimine for ADHD

Previous page Next page

Norbinaltorphimine is an opioid antagonist that has so far only been used in scientific research. Norbinaltorphimine is one of the few available highly selective kappa-opioid antagonists with a long-lasting effect.1
It is a non-stimulant.

A preclinical study in nicotine-exposed mice indicated a possible helpful effect of norbinaltorphimine in ADHD.2

Norbinaltorphimine increased dopamine and noradrenaline in the PFC in a similar way to methylphenidate, but with a significantly longer effect. At the same time, dopamine was not increased in the nucleus accumbens, which indicates a low risk of addiction.3

  1. Chavkin C, Cohen JH, Land BB (2019): Repeated Administration of Norbinaltorphimine Produces Cumulative Kappa Opioid Receptor Inactivation. Front Pharmacol. 2019 Feb 6;10:88. doi: 10.3389/fphar.2019.00088. PMID: 30787880; PMCID: PMC6373456. ↥

  2. McCarthy DM, Spencer TJ, Bhide PG (2023): Preclinical Models of Attention Deficit Hyperactivity Disorder: Neurobiology, Drug Discovery, and Beyond. J Atten Disord. 2023 Dec 12:10870547231215286. doi: 10.1177/10870547231215286. PMID: 38084074. ↥

  3. Zhang L, McCarthy DM, Eskow Jaunarajs KL, Biederman J, Spencer TJ, Bhide PG (2021): Frontal Cortical Monoamine Release, Attention, and Working Memory in a Perinatal Nicotine Exposure Mouse Model Following Kappa Opioid Receptor Antagonism. Cereb Cortex. 2021 Jan 1;31(1):483-496. doi: 10.1093/cercor/bhaa238. PMID: 32869057. ↥

Diese Seite wurde am 17.04.2024 zuletzt aktualisiert.
Previous page Next page